BridgeBio Pharma (BBIO) FCF Payout Ratio (2019)
BridgeBio Pharma (BBIO) posted FCF Payout Ratio of 0.69 for Q4 2019, down 4040.0% sequentially from 0.02 in Q1 2019.
Powered by 
Analysis
BridgeBio Pharma (BBIO) FCF Payout Ratio (2019) Analysis & Trends
BridgeBio Pharma has reported FCF Payout Ratio for 1 years, with the latest figure at 0.69 in Q4 2019.
- Quarterly FCF Payout Ratio changed N/A year-over-year to 0.69 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was 0.21 (changed N/A YoY) and the FY2020 annual result came in at 0.01, up 94.17% from the prior year.
- FCF Payout Ratio slipped to 0.69 in Q4 2019 per BBIO's latest filing, from 0.02 in the prior quarter.
- Over five years, FCF Payout Ratio peaked at 0.02 in Q1 2019 and troughed at 0.69 in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.17 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.07 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | BridgeBio Pharma | 14.65 Bn | 13.93 Bn | 228.63 Mn | - |